<DOC>
	<DOCNO>NCT00193206</DOCNO>
	<brief_summary>In trial evaluate ABI-007 gemcitabine epirubicin , utilize biweekly pegfilgrastim support , order improve upon effectiveness favorable toxicity triplet .</brief_summary>
	<brief_title>Neo-adjuvant Gemcitabine , Epirubicin , ABI-007 ( GEA ) Locally Advanced Inflammatory Breast Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive induction neo-adjuvant regimen postoperative adjuvant regimen : Induction Neo-adjuvant : Epirubicin + Gemcitabine + ABI-007 + Pegfilgrastim Postoperative Adjuvant : Gemcitabine + ABI-007 + Pegfilgrastim Upon completion chemotherapy , ER and/or PR+ patient receive Tamoxifen aromatase inhibitor physician discretion .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>To include study , must meet following criterion : Locally advanced/inflammatory adenocarcinoma breast 18 year age old Normal heart function Able perform activity daily live minimal assistance No prior chemotherapy breast cancer Adequate bone marrow , liver kidney function No evidence history significant cardiovascular abnormality Sentinel node axillary dissection Sign inform consent form You participate study follow apply : Pregnant breast feed History heart disease congestive heart failure Heart attack within previous 6 month Prior chemotherapy hormone therapy breast cancer History active uncontrolled infection Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Locally Advanced Breast Cancer</keyword>
	<keyword>Inflammatory Breast Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Abraxane</keyword>
	<keyword>nab Paclitaxel</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
</DOC>